SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

RODACKI, Melanie; ZAJDENVERG, Lenita; MILECH, Adolpho  and  OLIVEIRA, José Egídio Paulo de. Dosagem do peptídeo C sérico ao acaso em adultos com diagnóstico clínico de diabetes mellitus tipo 1. Rev. Assoc. Med. Bras. [online]. 2008, vol.54, n.3, pp.238-241. ISSN 0104-4230.

    1. Bakhtadze E, Borg H, Stenstrom G, Fernlund P, Arnqvist HJ, Ekbom-Schnell A, et al. HLA-DQB1 genotypes, islet antibodies and beta cell function in the classification of recent-onset diabetes among young adults in the nationwide Diabetes Incidence Study in Sweden. Diabetologia. 2006;49(8):1785-94. [ Links ]

    2. Borg H, Arnqvist HJ, Bjork E, Bolinder J, Eriksson JW, Nystrom L, Jeppsson JO, Sundkvist G. Evaluation of the new ADA and WHO criteria for classification of diabetes mellitus in young adult people (15-34 yrs) in the Diabetes Incidence Study in Sweden (DISS). Diabetologia. 2003;46(2):173-81. [ Links ]

    3. Gale E. Declassifying diabetes. Diabetologia. 2006;49(9):1989-95. [ Links ]

    4. Siraj ES, Reddy SS, Scherbaum WA, Abdulkadir J, Hammel JP, Fairman C. Basal and postglucagon C-peptide levels in Ethiopians with diabetes. Diabetes Care. 2002;25(4):453-7. [ Links ]

    5. Service FJ, Rizza RA, Zimmerman BR, Dyck PJ, OBrien PC, Melton LJ 3rd. The classification of diabetes by clinical and C-peptide criteria. A prospective population-based study. Diabetes Care. 1997;20(2):198-201. [ Links ]

    6. Vendrame F, Zappaterreno A, Dotta F. Markers of beta cell function in type 1 diabetes. Minerva Med. 2004;95(2):79-84. [ Links ]

    7. Sherry NA, Tsai EB, Herold KC. Natural history of beta cell function in type 1 diabetes. Diabetes. 2005;54(2):S32-S9. [ Links ]

    9. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am. 2001;30(4):935-82. [ Links ]

    10. Covic AM, Schelling JR, Constantiner M, Iyengar SK, Sedor JR. Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients. Kidney Int. 2000;58(4):1742-50. [ Links ]

    11. Berger B, Stenstrom G, Sundkvist G. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest. 2000;60(8):687-93. [ Links ]

    12. Keenan H, Doria A, Aiello LP, King GL. Positivity of C-peptide, GADA and IA2 antibodies in type 1 diabetic patients with extreme duration. Diabetes. 2006;55(Suppl 1):55A. [ Links ]

    13. Leslie RD, Williams R, Pozzilli P. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab. 2006;91(5):1654-9. [ Links ]

    14. Rodacki M, Zajdenverg L, Tortora RP, Reis FA, Albernaz MS, Bencke-Goncalves MR, et al. Characteristics of childhood and adult-onset type 1 diabetes in a multi-ethnic population. Diabetes Res Clin Pract. 2005;69(1):22-8. [ Links ]

    15. Rodacki M, Zajdenverg L, Albernaz MS, Bencke-Goncalves MR, Milech A, Oliveira JEP. Relationship between the prevalence of anti-glutamic acid decarboxylase autoantibodies and duration of type 1 diabetes mellitus in Brazilian patients. Braz J Med Biol Res. 2004;37(11):1645-50. [ Links ]

    16. Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care. 2006;29(5):970-5. [ Links ]